01 August 2006
Photodynamic effects of pyropheophorbide-a methyl ester in nasopharyngeal carcinoma cells
Chuan Shan Xu, Albert Wing Nang LeungMed Sci Monit 2006; 12(8): BR257-262 :: ID: 452845
Abstract
Background:Nasopharyngeal carcinoma (NPC) is one of the most common cancers, and exploring novel therapeutic modalities will improve the clinical outcomes. It has been confirmed that photodynamic therapy can efficiently deactivate malignant cells. The aim of the present study was to explore the photodynamic effects of pyropheophorbide-a methyl ester (MPPa) in CNE2 nasopharyngeal carcinoma cells.
Material/Methods: CNE2 cells were subjected to photodynamic therapy with MPPa, in which the drug concentration was 0.25 to 4 µM and light energy 1 to 8 J/cm[sup]2[/sup]. Photodynamic toxicity was investigated 24 h after treatment. Apoptosis was determined using flow cytometry with annexin V-FITC and propidum iodine staining and with nuclear staining with Hoechst 33258. The mitochondrial membrane potential (ΔΨm) was evaluated by Rhodamine 123 assay.
Results: There was no dark cytotoxicity of MPPa in the CNE2 cells at doses of 0.25–4 µM, and MPPa resulted in dose- and light-dependent phototoxicity. The apoptotic rate 8 h after PDT with MPPa (2 µM) increased to 16.43% under a light energy of 2 J/cm[sup]2[/sup]. Mitochondrial membrane potential (ΔΨm) collapsed when the CNE2 cells were exposed to 2 µM MPPa for 20 h and then 2 J/cm[sup]2[/sup] irradiation.
Conclusions:Photodynamic therapy with MPPa significantly enhanced apoptosis and the collapse of ΔΨm. This can be developed for treating nasopharyngeal carcinoma.
Keywords: Cell Death - drug effects, Membrane Potentials - drug effects, Mitochondrial Membranes - drug effects, Nasopharyngeal Neoplasms - drug therapy, Photochemotherapy - methods, Photosensitizing Agents - therapeutic use, Porphyrins - therapeutic use, Tumor Cells, Cultured
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952